Biotec Pharmacon enters a distribution agreement for Woulgan® in Austria

(Tromsø, 26 April 2019) Biotec Pharmacon’s (“Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has entered into a distribution agreement for Woulgan® with the Austrian distributor Publilog GmbH (Publilog). Under the terms of the agreement, Publilog becomes an exclusive partner for distribution of Woulgan® to the Austrian market, with Biotec supporting Publilog’s marketing division. Publilog is a … Continued ›

Notice of Annual General Meeting 15 May 2019

The Annual General Meeting in Biotec Pharmacon will be held on Wednesday 15. May 2019 at 11.00 CET at Hotel Continental, Stortingsgata 24/26, Oslo. The notice, registration and proxy form will be sent to the Company’s shareholders today and made available on www.newsweb.no and here under General meetings Shareholders who wish to attende the Annual General Meeting, in person … Continued ›

Biotec Pharmacon renews contract with largest customer within Animal Health business

Tromsø, Norway, 04 April 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary, Biotec BetaGlucans, has renewed its M-Glucan® contract with its largest customer within its Animal Health business. The Company will continue to supply and assist its long-standing customer, a major player in the Animal Health sector. Expected revenues, depending on the sales of the customer … Continued ›

Biotec Pharmacon’s subsidiary, ArcticZymes, granted €254.000 funding from Eurostars for a synthetic biology project

Tromsø, Norway, 2. April 2019 – Biotec Pharmacon (OSE: Biotec) announced today that its subsidiary, ArcticZymes, has been granted €254k as part of a collaborative project on the development of novel enzymes for synthetic biology. The project proposal was developed in collaboration with the University of Tromsø and Danish company, Legomics, has been positively evaluated … Continued ›

Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

Tromsø, Norway, 7 February 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro … Continued ›

Woulgan nominated for JWC awards

Woulgan is one of the finalists in the Journal of Wound Care Awards 2019 (JWC) for the most innovative product.  Biotec BetaGlucans is excited and proud to be nominated. The winner of the different categories will be announced in a ceremony to be held at Banking Hall in London on Friday 1st March 2019. The different categories and … Continued ›

Biotec Pharmacon finalises Post Market study on Woulgan®

Tromsø, Norway, 29 January 2019 – Biotec Pharmacon’s (OSE: Biotec) has announced that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in diabetic foot ulcer patients. Biotec BetaGlucans filed an application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) … Continued ›

Woulgan symposium at Harrogate

At the Wounds UK annual congress in Harrogate, November 2018 , Woulgan was included in the program with a satellite symposium. The presentation was set at a prime time in the program in the main auditorium. The symposium was chaired by Honorary Consultant Podiatrist Paul Chadwick and had the following speakers covering the topics: “Dramatically … Continued ›